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Background: “Hub-and-spoke” networks may be one solution to reduce the geographical inequality in access 
to liver transplantation (LT) and the growing demands on, and saturation of, LT-centres. It is not clear if such 
networks improve equity of access, deliver comparable patient outcomes or effect patient satisfaction. 
Methods: Patient outcomes in those assessed for LT between September 2011 and 2014 at spoke-centres 
were compared retrospectively with those assessed at the LT hub-centre. Patient satisfaction questionnaires 
were completed and changes in LT referral patterns were explored with data obtained directly from NHSBT. 
Findings: 655 patients (180 spoke; 475 hub) were assessed for LT. Patients referred from spoke centres were 
more likely to have viral hepatitis as an underlying aetiology (72/180 vs. 110/475; p<0.001) or HCC (48/180 vs. 
60/475; p<0.001) as an indication for LT and were more likely to be listed for LT when compared to hub 
patients (139/180 vs. 312/475, p=0.005). Mortality on the waiting list (9/123 vs. 25/269, p=0.57), waiting time 
to LT (101-days vs. 113-days, p=0.35) and MELD/UKELD score (p=0.24/0.26) in listed patients were equivalent 
as were one and three year patient and graft survival rates. Patient satisfaction rates were high at both types 
of centre, with significantly more patients preferring “locally delivered care” at spoke vs. hub centres 
(p<0.0001). Since the development of formal hub-and-spoke networks data from NHSBT based on postcode 
confirmed a significant increase in patients undergoing LT (160%) from spoke centres, whereas numbers 
assessed and transplanted from the hub-centre have remained static.  
Interpretation: Hub-and-spoke LT networks are effective in offering equivalent clinical outcomes, high patient 
satisfaction and alleviate clinical pressure on the hub-centre. They have to potential to help eliminate the 








 Liver disease in the United Kingdom (UK) is the third commonest cause of premature death with a 
400% increase in standardised mortality since the 1970’s and remains the glaring exception to the vast 
improvements made within UK health care over the last 30-years. (1-3) In England and Wales approximately 
60,000 patients have cirrhosis, with one and five-year survival rates of just 0.55 and 0.31 respectively for those 
with a previous liver related hospital admission. (4, 5) There is a significant and worrisome geographical 
disparity in mortality rates for cirrhosis, such that premature death rates from chronic liver disease in England 
vary 3.9 fold between primary care trusts. (1, 4) The geographical disparity in liver disease is not limited to 
mortality, but also access to specialist services, diagnosis and management. In 2014 and 2015 The Lancet 
commission highlighted these issues and proposed stratergies to improve outcomes for patients with liver 
disease, including hub-and-spoke referral pathways to improve access to liver transplantation (LT). (1, 6) It is 
hoped the engagement of spoke centres via LT will not only improve the geographical disparity in access to LT 
but also have a secondary effect on improving geographical inequality throughout all aspects of liver disease. 
 Liver Transplantation is a life-saving, life enhancing procedure for patients with decompensated 
chronic liver disease (CLD) with survival rates of 90% and 80% at 1- and 5-years respectively. (7) The number of 
transplants performed annually in the UK is increasing, but lags behind the number needing LT which has more 
than doubled between 2008 and 2015. (8)  A failure to invest in, or to develop, LT services over the last 20-
years means LT centres are in a poor position to adapt to increased demand, (9) while the number of LT 
centres within England (six) remaining static over that time. The current NHSBT 2020 strategy to increase the 
number of LT performed by 50% by 2020 (by donor optimisation, improved organ offering procedures, policies 
to encourage organ donation and use of deceased after cardiac death (DCD) organs) raises concerns regarding 
the capacity of LT centres to cope with the anticipated increase. (9, 10) An additional challenge regarding LT 
within the UK is that access to LT services is not geographically equitable; LT rates in the UK are highest with 
geographical proximity LT centres, as opposed to reflecting regions with the greatest disease burden. (4)   
Historically, patients being considered for LT are referred to a particular LT centre where pre-transplant 
optimisation, the LT assessment process, waiting list management, surgery and post-operative care are 
delivered. It is accepted that the current configuration of LT services in England reflect historical enterprise and 
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centres were not established with the epidemiology of CLD, geographical variation in disease burden or  
patient need in mind. (10) Bilateral arrangements between LT and regional centres have been adopted ad hoc 
as a potential solution to improve access and to cope with increased demand using a ‘hub and spoke’ model, 
(10) which has proved effective in other conditions including stroke and cancer care. (11-13)  
Our view is that established networks with spoke centres defined by need based on patient population 
and geographical remoteness in conjunction with local and central enthusiasm is the best model to deliver LT 
with mutual benefits for the hub, spoke and the patient (Table 1). Whilst recommended as a model for LT care, 
the hub-and-spoke model has not been assessed with regards to outcomes, patient satisfaction or impact on 
improving geographical access to LT. (6, 10) 
The aim of the current study was to determine if LT ‘hub-and-spoke’ network arrangements delivered 
equitable clinical outcomes and patient satisfaction when compared to patients managed solely at the hub.  
Moreover we assessed if access to LT (via number of LT’s performed per region over time) increased with the 
introduction of a hub-and-spoke network. 
Patients and Methods 
In September 2011, formal network arrangements were established between the RFH and four specialist 
tertiary liver units (The Royal London Hospital, London (RLH), St Mary’s Hospital, London (SMH), The Royal 
Devon & Exeter, Exeter (RDE) and United Hospitals Bristol, Bristol (UHB)). Patients were defined as managed at 
the hub alone (RFH) or at one of the four spoke-centres. 
Service level agreements (SLA’s) for assessment, management on the waiting list and post-operative care 
were pre-defined; all aspects of pre- and post-operative care, short of LT surgery and immediate post-
operative recovery were managed at the spoke-centres with regular outreach sessions provided by RFH 
physicians. (Figure 1). Data were collected retrospectively on all patients referred and assessed for LT at the 
RFH between September 2011 and September 2015 and these patients were followed until the censor point in 
May 2016. Patients referred or transplanted for acute liver failure were excluded. Baseline characteristics were 
collated (Table 2). Patients were classified as having decompensated CLD if they had a qualifying UKELD score 
and an episode of hepatic decompensation, irrespective of HCC status and patients were classified as having 
HCC when this was their only indication for LT. Significant clinical outcomes were recorded including listing for 
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LT, waiting time to LT, death on the waiting list, access to DBD organs and 1- and 3-year patient and graft 
survival rates were recorded.  
Patient satisfaction was assessed was assessed at routine post-operative clinic review (supplementary 
data) in all spoke patients and 50 consecutive hub patients. These focused on patient perception of 
communication, safety, visibility on the waiting list and overall satisfaction. 
Changes in the volume of patients assessed for LT or undergoing LT at the hub or the areas serving 
the spoke-centres were compared from September 2010 to September 2011 and after formal establishment of 
the hub-and-spoke networks. NHSBT were contacted to provide complementary geographical data to ensure 
any increase in activity could be attributable to the network as opposed to re-allocation of activity from other 
LT centres.  
Statistical Analysis:  
Data are presented throughout using median and range for numerical values. To determine whether 
significant differences existed between groups, the Students t test, or the Mann-Whitney-U non-parametric 
method as appropriate was applied. Differences in nominal data were compiled either by the Chi squared test 
or using a Fisher’s exact test when the number was less than 5 in any given cell of a 2x2 table. A p value of 
<0.05 was considered to be of statistical significance. Kaplan-Meier curves were constructed to analyse graft 
and patient survival over time.  All statistical analysis was performed using SPSS statistical software package 
version 21 (SPSS Inc., Chicago, IL). 
Results 
Assessment for Liver Transplantation  
Over the study period 655 patients were assessed for LT; 180 (27%) from spoke-centres and 475 
(73%) from the hub. The 179 spoke-centre patients were referred from either the RLH (n=74, 41%), SMH 
(n=47, 26%), UHB (n=40, 22%) and RDE (n=19, 11%). Hub-patients were either referred from RFH hepatologists 
(n=170, 36%) or physicians at other centres without formal links established (n=307, 64%). 
The indications for assessment overall were decompensated CLD (n=547, 83.5%) with a median 
MELD/UKELD score of 15/54 or Hepatocellular Carcinoma (HCC) in the absence of hepatic decompensation 
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(n=108, 16.5%). The commonest underlying aetiologies were alcohol related, hepatitis C related or primary 
sclerosing cholangitis. A greater proportion of patients from spoke-centres had viral hepatitis as the underlying 
aetiology (72/180 vs. 110/475; p<0.001). A greater proportion of patients were assessed for HCC at spoke vs 
hub centres (48/180 vs. 60/475; p<0.001). Liver disease severity scores in those assessed for decompensated 
CLD were not statistically different between the hub-and-spoke centres. These data are summarised in Table 2.  
Overall 68.9% (n=451) of patients assessed were listed for LT; the primary indication being either 
decompensated CLD in 82% and HCC in the remainder. Overall, patients from spoke-centres were more likely 
to be listed for LT than those assessed from the hub (139/180 vs. 312/475, p=0.005). Patients from the spoke 
were more likely to be listed for HCC (36/139 vs 45/312, p=0.003) whereas patients from the hub were more 
likely to be listed for decompensated CLD (p=0.003). There were no significant statistical differences between 
listed hub-and-spoke patients with respect to age, gender and, MELD/UKELD in those listed for 
decompensated CLD. (Table 2) 
The commonest reasons for a patients not being listed for LT following assessment were “too 
deconditioned/unfit” (n=70, 11%) and “too well” (n=45, 7%); When comparing patients assessed from the 
spoke-centre vs. hub-centre there was no significant difference in those patients deemed “too 
deconditioned/unfit” (12/41 vs. 58/163, p=0.57) or “too well” (9/41 vs. 36/163, p=z). 
Waiting list outcomes  
There were 451 patients listed for LT comprising 139 (31%) from spoke-centres and 312 (69%) from 
the hub. A total of 275 (62%) underwent LT; 57 (13%) remain on the waiting list; 59 (13%) were removed from 
the waiting list and and 34 (7.5%) died awaiting LT. The proportion of patients that died awaiting LT was similar 
in spoke-centres and the hub (9/123 vs. 25/269, p=0.57); the median MELD score (19 vs. 19) and UKELD scores 
(59 vs. 59) were similar at listing in those that died awaiting LT from the spoke and the hub; the time from 
listing to death was similar in spoke-centres and the hub (64-days vs 78-days, p=0.91). (Table 3) 
Transplanted patients 
A total of 301/451 (67%) listed patients underwent LT. The likelihood of undergoing LT was similar in 
spoke-centres and the hub (99/122 vs 202/266, p=0.30); waiting times to LT were similar in spoke-centres and 
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the hub (101-days vs. 113-days, p=0.35); DBD organ usage was similar in spoke-centres and the hub (76/99 vs. 
154/202, p=0.87). Patient survival post LT was similar between the spoke-centres and the hub at 1-year (94/99 
vs. 192/202 p=0.78) and 3-years (92/99 vs. 186/202 p=0.78) (Figure 2a). Graft survival was similar in spoke-
centres and the hub at 1-year (93/99 vs. 187/202 p=0.34) and 3-years (92/99 vs. 183/202 p=0.34) post LT 
(Figure 2b). 
Patient satisfaction 
 The questionnaire was completed by 74% (73/99) of spoke-centre patients and by 50 consecutive hub 
patients at their routine post LT clinic visits.  Completion rates from the spoke centres were RLH (24/40, 60%), 
SMH (19/28, 68%), UHB (22/22, 100%) and RDE (8/9, 89%). 
 Over 90% of patients managed at spoke centres felt there was good bilateral communication between 
the hub and spoke-centres, 95% did not feel disadvantaged by having their pre- and post-LT care managed 
away from the hub centre and 96% stated an appreciation for “locally” delivered specialist care.  When 
questioned on reasons for preferring “locally” delivered specialist care; further inquiry revealed the main 
reasons for preferring “local” specialist care were “familiar hospital/doctor” (87%), “proximity to home/travel 
time” (81.4%) and “travel cost” (37%). Patient satisfaction with care received at the spoke-centre was ranked 
at 9.4/10. 
 Of those surveyed at the hub, the RFH was the patients “local” hospital in 12%. In comparison to 
spoke-centre patients only 25% of hub patients stated they would have preferred “locally” delivered pre- and 
post-LT care (11/50 vs. 70/73, p=<0.0001), with loss of confidence in their local centre being cited as the main 
reason. The reasons stated for a preference for “local” care were travel time and cost (75% 8/11) with only 
27% (3/11) stating familiarity as a reason.  Overall satisfaction with care received at the hub was ranked at 9.4 






Improving access to LT: historical comparison 
 In the year prior to formal hub-and-spoke networks being established there were 18 patients 
assessed of which 9 were transplanted from geographical areas served by prospective spoke centres. Since the 
formal hub-and-spoke networks were introduced in 2011 there has been on average a 120% increase in 
patients assessed and a 160% increase in patient undergoing LT from the spoke centres. In comparison at the 
hub-centre there has been a 12% increase in patients assessed and a 9% reduction in patients undergoing LT. 
Data direct from NHSBT on the number of transplants performed in designated “hub” catchment areas was 
obtained from 2009 – 2015. This confirmed an average increase of 154% in transplant activity since the 
development of Hub centres. (14) 
 
Discussion 
In this study we have demonstrated for the first time that LT care delivered via hub-and-spoke 
networks is effective with equitable clinical outcomes regarding waiting times for LT, organ utilisation and, 1- 
and 3-year graft and patient survival rates. Moreover we have shown that patient satisfaction with “locally 
delivered specialist care” is excellent and that geographical access to LT for patients has increased significantly 
since the advent of such networks in regions served by dedicated spoke-centres.  
An anxiety and perhaps reticence of some LT centres/physicians towards the hub-and-spoke network 
is that LT waiting list patients could be disadvantaged via a “lack of expertise” and “lack of visibility” to the 
transplanting hub-centre, resulting in a longer wait for LT and higher wait-list mortality. This study has shown 
no difference in waiting list mortality (p=0.57), wait for LT (p=0.35), LT rates (p=0.3) and delisting rates 
(p=0.51) when comparing hub-and-spoke patients. The equity between centres is likely to reflect equivalent 
clinical care provided by motivated spoke physicians and the robust communication networks in place 
between all our hub-and-spoke centres. Devolving post-LT management largely to spoke-centres is likely to 
cause similar anxieties amongst some LT centres/physicians with regards to inferior experience and expertise 
in the management of post-LT complications at spoke-centres. This study has shown these anxieties not to be 
borne out with equivalent 1- and 3-year graft and patient survival in hub-and-spoke centres. Less robust 
clinical endpoints which may reflect the more subtle nuances of the quality of post-LT care such as renal 
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function, cardiovascular, infectious and malignant complications have yet to be evaluated between hub-and-
spoke centres but are additional important future parameters which should be assessed in ensuring 
equivalence. (15) 
Our study has highlighted some important differences between the hub-and-spoke centres. Firstly 
patients from spoke-centres were significantly more likely to be listed for (139/180 vs. 312/475, p=0.005), and 
have HCC as an indication for (36/139 vs. 45/312, p=0.003) LT. One may argue that the difference in likelihood 
of being listed may be a reflection of spoke-centres referring in only “cast iron cases”.  However no significant 
difference in assessed patients MELD/UKLED scores in decompensated CLD (p=0.24/0.26), age (p=0.49) or 
those deemed too deconditioned for LT (p=0.57) was noted suggesting case mix is similar. The differences the 
proportion listed between hub-and-spoke centres is likely to reflect subtle difference in the assessment 
process. Patients being considered for LT at spoke-centres undergo initial screening assessment investigations 
(echocardiography, pulmonary function tests, computed tomography, exercise testing etc) and are discussed 
in principle with the hub-centre before a formal LT assessment is commenced, thus ruling out early those 
patients with prohibitive co-morbidities; whereas at the spoke centre potential LT patients are admitted for a 
5-day assessment where all LT assessment investigations are performed and then the patient is formally 
discussed in the listing meeting at the end of the week, and those with prohibitive comorbidities declined. The 
difference in HCC as an indication for LT between the hub and spoke-centre is more difficult to explain. It may 
reflect geographical differences in aetiology as viral hepatitis (a strong risk factor for HCC) was also significantly 
higher in the spoke population (p<0.001).  
The second difference worthy of discussion is that although patient satisfaction with the LT process 
was high at both the hub-and-spoke centres (ranked 9.4/10), patients at spoke-centres valued a familiar 
hospital/doctor (87%) as a reason for “local” care and 98.4% reported “feeling safe” being managed by their 
local centre. Conversely hub-patients cited a lack of confidence in their “local” centre for preferring care 
delivered centrally at the hub. These differences, although not evaluated in this study, are likely to be 
multifactorial with many contributing factors including; highly engaged and motivated spoke physicians, 
ongoing dialogue between spoke and hub physicians via regular out-reach clinics, the presence of a RFH 
physician at spoke out-reach clinics, financial investment in spoke centres via SLA’s alongside possible 
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disengagement of non-spoke local physicians due to a perception of a loss of autonomy in the management of 
their patient and finally less robust communication pathways between non-spoke local centres and the RFH.  
 Spoke-centres should be established where there is a clinical need either secondary to geographical 
remoteness or due need based on patient population density. (6, 10) In this study two of our spoke-centres 
(RLH and SMH) were established based on high patient populations with CLD and both are within an 8-mile 
radius of the hub-centre, whereas the remaining two centres (UHB and RDE) were established due to 
geographical remoteness being 120- and 170-miles from the hub-centre respectively. Despite differences in 
patient volume and distance from the LT-hub a sub-analysis of outcomes between the centres reassuringly 
showed no significant differences indicating that both indications for a spoke centre are valid and effective.  
(Supplementary data: table 1)  
Finally we have shown an increase of 160% in transplant activity from hub centres, since the 
development of networks. It could be argued that this increase in activity merely reflects taking activity away 
from other LT centres and is not due to improved geographical access to LT. Data obtained direct from NHSBT 
however on number of transplants based on postcode has also shown a similar increase (154%) in activity 
since the setting up of the RFH networks. (14) This strongly adds weight to the hypothesis that the increase in 
activity is due to improved access to LT offered by the networks, as opposed to re-allocation of activity 
between LT centres. 
The study does have limitations which highlight areas for future exploration. Firstly with regards to 
patient satisfaction only post-LT patients were evaluated, not those who remained on the LT waiting list or had 
been delisted. Clearly these are sub-sets of patients at different stages in the LT process and their satisfaction 
and perception of the care they are receiving could differ. Secondly the RFH has 2 additional outreach centres 
(which contributed to 5.6% (17/301) of the total number transplanted) where the LT assessment process / 
post LT management is a “half way house” between fully devolved spoke-care and unilateral hub-care. For the 
purpose of the study due to a lack of provision for pre transplant assessment within the SLA and some 
networks only recently formed these patients were classed as belonging to the hub-centre and potentially 
could have skewed our results. It remains to be evaluated if this model is cost effective or improves inequality 
in other aspects of service delivery in liver disease. 
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In conclusion hub-and-spoke LT networks are effective offering equivalent clinical outcomes for 
patients, with high patient satisfaction scores, alleviate clinical pressures on the hub-centre and have the 
potential to contribute to eliminating the geographical imbalance between mortality rates, service provision 
and clinical need in patients with advanced chronic liver disease.  
 
 
Table 1: Potential benefits of hub-and-spoke delivery of LT care throughout the UK 
Patient Hub Spoke 
Care delivered locally 
 
Potential to improve equity of access 
to LT 
 
Long-term continuity of care 
 
Growth of transplant activity 
 
Foster closer working relationships 
with referrers 
 
Reduce pressure on resources 
 
Empowerment / service development 
 
Formal referral pathways 
 
 





















Table 2: Patient data (a) assessed and (b) listed for LT from hub and spoke centres (* p<0.05) 
(a) 




          
Patients, n 655 180 475 - 
          








          
Age, median, (range), years 57 (17-74) 56 (17-73) 57 (19-74) 0.49 
          
Aetiology        
ALD, n (%) 207 (31.6) 51 (28.3) 156(32.8)   
HCV, n (%) 144 (22) 55 (30.6) 89 (18.7) <0.05 
PSC, n (%) 70 (10.7) 19 (10.6) 51 (10.7)   
NAFLD, n (%)  58 (8.9) 15 (8.3) 43 (9.1)   
AIH, n (%) 40 (6.1)  8 (4.4) 32 (6.7)   
HBV, n (%) 38 (5.8) 17 (9.4) 21 (4.4) <0.05 
PBC, n (%) 35 (5.3) 6 (3.3) 29 (6.1)   
Other, n (%) 58 (9) 9 (5) 49 (10)   








DCLD/HCC, n (%) 



























          
Patients, n 451 139 312 - 
          








          
Age, median, (range), years 56 (17-74) 55 (17-73) 57 (19-74) 0.82 
          
Aetiology        
ALD, n (%) 124 (27.5) 40 (28.8) 84 (26.9)   
HCV, n (%) 111 (24.6) 44 (31.7) 67 (21.5)   
PSC, n (%) 52 (11.5) 16 (11.5) 36 (11.5)   
NAFLD, n (%) 35 (7.8) 8 (5.8) 27 (8.7)   
AIH, n (%) 33 (7.3) 7 (5.0) 26 (8.3)   
HBV, n (%) 29 (6.4) 14 (10.1) 15 (4.8)   
PBC, n (%) 22 (4.9) 5 (3.6) 17 (5.4)   
Other, n (%) 45 (10) 5 (4) 40 (12)   








DCLD/HCC, n (%) 
































Table 3: Outcomes for patients listed for transplantation (* p<0.05) 
 
Overall Spoke Hub 
Spoke vs 
Hub p value 
          
Listed, n (% assessed) 451 (68.9) 139 (77.2) 312 (65.7) 0.005* 
          
Delisted, n (%) 59 (13.1) 16 (11.5) 43 (13.8) 0.61 
Deconditioned, n (% of delisted) 20 (33.9) 5 (31.3) 15 (34.9)   
Re-compensation, n (% of delisted) 16 (27.1) 3 (18.8) 13 (30.2)   
Progression outside HCC criteria, n (% of 
delisted) 
11 (18.6) 5 (31.3) 6 (14.0)   
Breaking patient contract, n (% of delisted) 9 (1.4) 2 (12.5) 7 (16.3)   
Patient choice, n (% of delisted) 3 (0.5) 1 (6.3) 2 (4.7)   
     
Transplanted, n (% on WL) 301 (76.8) 99 (80.5) 202 (75.1) 0.30 
DBD organ, n (% transplanted) 230 (76.4) 76 (76.8) 154 (76.2) 0.87 
Time from listing to transplant, median 
(range), days 
106 (1-1107) 101 (1-616) 113 (1-1107) 0.35 
     
Still waiting, n(% on WL) 57 (12.6) 15 (12.2) 42 (20.8) 0.37 
          
Died on WL, n(%) 34 (7.5) 9 (7.0) 25 (9.3) 0.57 
MELD, median (range) 19 (8-36) 19 (14-32) 19 (8-36) 0.71 
UKELD, median (range) 59 (48-72) 59 (50-67) 59 (48-72) 0.96 
Time from listing to death, median (range), 
days 






















5 day inpatient 
admission for 
work up 
DECISION TO LIST 
RFH Wait list 
management 
RFH Liver transplant 









2 day ‘day stay’ 













St Marys RLH RD&E UHB 
Sub group 
 p value 
              
Patients, n 180 48 74 18 40 - 
              












              
Age, median (range), years 56 (17-73) 56 (17-74) 55 (17-73) 57 (19-74) 54 (23-71)   
              
Aetiology            0.013* 
ALD n(%) 51 (28.3) 10 (20.8) 12 (16.2) 12 (66.7) 17 (42.5) * 
HCV n(%) 55 (30.6) 18 (37.5) 23 (31.1) 3 (16.7) 11 (27.5)   
PSC n(%) 19 (10.6) 8 (16.7) 8 (10.8) 0 (0.0) 3 (7.5)   
NAFLD n(%) 15 (8.3) 2 (4.2) 7 (9.5) 3 (16.7) 3 (7.5)   
AIH n(%)  8 (4.4) 0 (0.0) 7 (9.5) 0 (0.0) 1 (2.5)   
HBV n(%) 17 (9.4) 6 (12.5) 11 (14.9) 0 (0.0) 0 (0.0)   
PBC n(%) 6 (3.3) 3 (6.3) 1 (1.4) 0 (0.0) 3 (7.5)   
Non cirrhotic indication n(%) 2 (1.1) 0 (0.0) 1 (1.4) 0 (0.0) 1 (2.5)   
Post OLT ind n(%) 2 (1.1) 0 (0.0) 1(1.4) 0 (0.0) 0 (0.0)   
Cryptogenic n(%) 1 (0.6) 1 (2.1) 1 (1.4) 0 (0.0) 1 (2.5)   
Metabolic n(%) 1 (0.6) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.5)   
Other n(%) 3 (1.7) 0 (0.0) 2 (2.7) 0 (0.0) 1 (2.5)   











DCLD/HCC n, (% DCLD) 
MELD (DCLD), median, (range) 15 (6-45) 14 (6-30) 14 (7-31) 18 (11-25) 16 (7-40) 0.87 
UKELD (DCLD), median, (range) 55 (0-67) 54 (48-65) 54 (45-67) 58 (0-65) 55 (43-67) 0.21 
              
Listed, n (% assessed) 139 (77.2) 36 (75.0) 60 (81.1) 14 (77.8) 29 (72.5) 0.74 
              
Delisted, n (% listed) 16 (11.5) 3 (8.3) 8 (13.3) 1 (7.1) 4 (13.8) 0.1 
Deconditioned, n (% of delisted) 5 (31.3) 0 (0.0) 4 (50.0) 0 (0.0) 1 (25.0)   
Re-compensation, n (% of delisted) 3 (18.8) 0 (0.0) 1 (12.5) 1 (100) 1 (25.0)   
Progression outside HCC criteria, n 
(% of delisted) 
5 (31.3) 1 (33.3) 3 (37.5) 0 (0.0) 1 (25.0)   
Breaking patient contract, n (% of 
delisted) 
2 (12.5) 2 (66.7) 0 (0.0) 0 (0.0) 0 (0.0)   
Patient choice, n (% of delisted) 1 (6.3) 0 (0.0) 0 (0.0) 0 (0.0) 1 (25.0)   
              
Transplanted, n (% on WL) 99 (80.5) 29 (87.9) 43 (84.3) 9 (69.2) 18 (72.0) 0.27 
DBD organ, n (% transplanted) 76 (76.8) 20 (69.0) 31 (72.1) 9 (100) 16 (89.0) 0.38 
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Time from listing to transplant, 











              
Still waiting, n (% on WL) 15 (12.2) 2 (6.1) 6 (11.5) 1 (7.7) 6 (24.0) 0.2 
              
Died on WL, n (% on WL) 9 (7.0) 2 (6.0) 3 (5.8) 3 (23.1) 1 (4.0) 0.14 
MELD, median (range) 19 (14-32) 19 (17-20) 16 (14-20) 19 (15-19) 32 0.29 
UKELD, median (range) 59 (50-67) 58 (56-60) 59 (50-62) 59 (56-65) 67 0.67 












Supplementary data:  Questionnaire 
Telephone interview with post-transplant patients through at spoke-centres  
Did you feel there was good communication between the satellite liver transplant unit 
and the transplant centre? 
 
Yes definitely [ ]  Yes to some extent [ ]   No [ ] 
 
Did you appreciate your pre-transplant care being delivered locally? 
 
Yes [ ]   No [ ] 
 
If so, please rank in order the top three reasons you appreciated about being managed 
in Bristol Royal Infirmary? 
 
1. Near Home       [ ]  
2. Time travelling to London     [ ] 
3. Cost of travelling to London     [ ] 
4. Being in a familiar hospital     [ ] 
5. Being managed by a familiar doctor    [ ] 
6. Other  [ ______________________________________________ ] 
 
 
Did you feel disadvantaged when waiting for a transplant by not being managed 
directly by the Royal Free? 
 
Yes, definitely [ ]  Yes to some extent [ ]  No [ ] 
 
 




Did you feel safe following discharge from the Royal Free, to have your care managed 
by Bristol Royal Infirmary? 
 
 Yes, definitely [ ]  Yes to some extent [ ] No [ ] 
 
 
Overall how would you rate your satisfaction with the liver transplantation service 
delivered between Bristol Royal Infirmary and the Royal Free Hospital? 
 
Rank 1 (poor) – 10 (excellent)   [    ] 
 
 





Appendix 1: (b) Telephone interview with post-transplant patients at hub centre 
Did you feel there was good communication between the liver transplant team and 
yourselves? 
 
Yes definitely [ ]  Yes to some extent [ ]   No [ ] 
 
If your pre-transplant care could be delivered at your local hospital, would you prefer 
this? 
 
Yes [ ]   No [ ] 
 
If so, please rank in order the top three reasons you would prefer to be managed at 
your local hospital? 
 
7. Near Home       [ ]  
8. Time travelling to London     [ ] 
9. Cost of travelling to London     [ ] 
10. Being in a familiar hospital     [ ] 
11. Being managed by a familiar doctor    [ ] 
12. Other  [ ______________________________________________ ] 
 
 





Overall how would you rate your satisfaction with the liver transplantation service at 
the Royal Free Hospital? 
 
Rank 1 (poor) – 10 (excellent)   [    ] 
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